ReP USP - Resultado da busca

Artigo de periodico
Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial (2023)
Burkhardt, Gerrit; Kumpf, Ulrike; Crispin, Alexander; Goerigk, Stephan; Andre, Elisabeth; Plewnia, Christian; Brendel, Bettina; Fallgatter, Andreas; Langguth, Berthold; Brunoni, Andre Russowsky
Source: Lancet. Unidade: FM
Subjects: ESTUDOS MULTICÊNTRICOS, DEPRESSÃO, ESTIMULAÇÃO MAGNÉTICA TRANSCRANIANA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURKHARDT, Gerrit et al. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial. Lancet, v. 402, n. 10401, p. 545-554, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57346. Acesso em: 06 out. 2024.
APA
Burkhardt, G., Kumpf, U., Crispin, A., Goerigk, S., Andre, E., Plewnia, C., et al. (2023). Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial. Lancet, 402( 10401), 545-554. doi:10.1016/S0140-6736(23)00640-2
NLM
Burkhardt G, Kumpf U, Crispin A, Goerigk S, Andre E, Plewnia C, Brendel B, Fallgatter A, Langguth B, Brunoni AR. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial [Internet]. Lancet. 2023 ; 402( 10401): 545-554.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57346
Vancouver
Burkhardt G, Kumpf U, Crispin A, Goerigk S, Andre E, Plewnia C, Brendel B, Fallgatter A, Langguth B, Brunoni AR. Transcranial direct current stimulation as an additional treatment to selective serotonin reuptake inhibitors in adults with major depressive disorder in Germany (DepressionDC): a triple-blind, randomised, sham- controlled, multicentre trial [Internet]. Lancet. 2023 ; 402( 10401): 545-554.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57346
Artigo de periodico
The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 (2022)
Khanh Bao Tran; Lang, Justin J; Compton, Kelly; Xu, Rixing; Acheson, Alistair R; Henrikson, Hannah Jacqueline; Kocarnik, Jonathan M; Penberthy, Louise; Aali, Amirali; Alonso, Nivaldo
Source: Lancet. Unidade: FM
Subjects: CONSENSO, NEOPLASIAS, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KHANH BAO TRAN, et al. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, v. 400, n. 10352, p. 563-591, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)01438-6. Acesso em: 06 out. 2024.
APA
Khanh Bao Tran,, Lang, J. J., Compton, K., Xu, R., Acheson, A. R., Henrikson, H. J., et al. (2022). The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 400( 10352), 563-591. doi:10.1016/S0140-6736(22)01438-6
NLM
Khanh Bao Tran, Lang JJ, Compton K, Xu R, Acheson AR, Henrikson HJ, Kocarnik JM, Penberthy L, Aali A, Alonso N. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 [Internet]. Lancet. 2022 ; 400( 10352): 563-591.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)01438-6
Vancouver
Khanh Bao Tran, Lang JJ, Compton K, Xu R, Acheson AR, Henrikson HJ, Kocarnik JM, Penberthy L, Aali A, Alonso N. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019 [Internet]. Lancet. 2022 ; 400( 10352): 563-591.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)01438-6
Artigo de periodico
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study (2022)
Tromp, Tycho R.; Hartgers, Merel L. ; Hovingh, G. Kees; Vallejo-vaz, Antonio J. ; Ray, Kausik K.; Soran, Handrean; Freiberger, Tomas; Bertolini, Stefano; Harada-shiba, Mariko; Blom, Dirk J.
Source: Lancet. Unidade: FM
Subjects: ESTUDOS DE COORTES, HIPERCOLESTEROLEMIA, CRIANÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TROMP, Tycho R. et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, v. 399, n. 10326, p. 719-728, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50469. Acesso em: 06 out. 2024.
APA
Tromp, T. R., Hartgers, M. L., Hovingh, G. K., Vallejo-vaz, A. J., Ray, K. K., Soran, H., et al. (2022). Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, 399( 10326), 719-728. doi:10.1016/S0140-6736(21)02001-8
NLM
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-shiba M, Blom DJ. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study [Internet]. Lancet. 2022 ; 399( 10326): 719-728.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50469
Vancouver
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-shiba M, Blom DJ. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study [Internet]. Lancet. 2022 ; 399( 10326): 719-728.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50469
Artigo de periodico
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) (2022)
Giudice, Linda C; As-sanie, Sawsan; Ferreira, Juan C. Arjona; Becker, Christian M; Abrão, Maurício Simões ; Lessey, Bruce A; Brown, Eric; Dynowski, Krzysztof; Wilk, Krzysztof; Li, Yulan
Source: Lancet. Unidade: FM
Subjects: CO-TERAPIA, GONADOTROFINAS, ENDOMETRIOSE, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUDICE, Linda C et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, v. 399, n. 10343, p. 2267-2279, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00622-5. Acesso em: 06 out. 2024.
APA
Giudice, L. C., As-sanie, S., Ferreira, J. C. A., Becker, C. M., Abrão, M. S., Lessey, B. A., et al. (2022). Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). Lancet, 399( 10343), 2267-2279. doi:10.1016/S0140-6736(22)00622-5
NLM
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5
Vancouver
Giudice LC, As-sanie S, Ferreira JCA, Becker CM, Abrão MS, Lessey BA, Brown E, Dynowski K, Wilk K, Li Y. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) [Internet]. Lancet. 2022 ; 399( 10343): 2267-2279.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00622-5
Artigo de periodico
End compulsory drug treatment in the Asia-Pacific region (2022)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Source: Lancet. Unidade: IP
Subjects: CENTROS DE REABILITAÇÃO, REABILITAÇÃO DA DROGA, DEPENDENTES QUÍMICOS, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
End compulsory drug treatment in the Asia-Pacific region. Lancet, v. 29 jan.-4 fe 2022, n. 10323, p. 419-421, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00003-4. Acesso em: 06 out. 2024.
APA
End compulsory drug treatment in the Asia-Pacific region. (2022). End compulsory drug treatment in the Asia-Pacific region. Lancet, 29 jan.-4 fe 2022( 10323), 419-421. doi:10.1016/S0140-6736(22)00003-4
NLM
End compulsory drug treatment in the Asia-Pacific region [Internet]. Lancet. 2022 ; 29 jan.-4 fe 2022( 10323): 419-421.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00003-4
Vancouver
End compulsory drug treatment in the Asia-Pacific region [Internet]. Lancet. 2022 ; 29 jan.-4 fe 2022( 10323): 419-421.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00003-4
Artigo de periodico
Archbishop Desmond Tutu and the universality of health and human rights (2022)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Source: Lancet. Unidade: IP
Subjects: DESIGUALDADES SOCIAIS, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Archbishop Desmond Tutu and the universality of health and human rights. Lancet, v. 5-11 fe 2022, n. 10324, p. 503-504, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00121-0. Acesso em: 06 out. 2024.
APA
Archbishop Desmond Tutu and the universality of health and human rights. (2022). Archbishop Desmond Tutu and the universality of health and human rights. Lancet, 5-11 fe 2022( 10324), 503-504. doi:10.1016/S0140-6736(22)00121-0
NLM
Archbishop Desmond Tutu and the universality of health and human rights [Internet]. Lancet. 2022 ; 5-11 fe 2022( 10324): 503-504.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00121-0
Vancouver
Archbishop Desmond Tutu and the universality of health and human rights [Internet]. Lancet. 2022 ; 5-11 fe 2022( 10324): 503-504.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00121-0
Artigo de periodico
Political science and global health policy (2022)
Gómez, Eduardo J; Singh,Prerna; Shiffman, Jeremy ; Barberia, Lorena
Source: Lancet. Unidade: FFLCH
Assunto: POLÍTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GÓMEZ, Eduardo J et al. Political science and global health policy. Lancet, v. 399, n. ju 2022, p. 2080-2082, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(22)00923-0. Acesso em: 06 out. 2024.
APA
Gómez, E. J., Singh, P., Shiffman, J., & Barberia, L. (2022). Political science and global health policy. Lancet, 399( ju 2022), 2080-2082. doi:10.1016/S0140-6736(22)00923-0
NLM
Gómez EJ, Singh P, Shiffman J, Barberia L. Political science and global health policy [Internet]. Lancet. 2022 ; 399( ju 2022): 2080-2082.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00923-0
Vancouver
Gómez EJ, Singh P, Shiffman J, Barberia L. Political science and global health policy [Internet]. Lancet. 2022 ; 399( ju 2022): 2080-2082.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(22)00923-0
Artigo de periodico
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights (2021)
Beyrer, Chris (comentar) ; Paiva, Vera Silvia Facciolla (comentar)
Source: Lancet. Unidade: IP
Subjects: VACINAÇÃO, COVID-19, DIREITOS HUMANOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. Lancet, v. 397, n. 10284, p. 1524-1527, 2021Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)00708-X. Acesso em: 06 out. 2024.
APA
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. (2021). Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights. Lancet, 397( 10284), 1524-1527. doi:10.1016/S0140-6736(21)00708-X
NLM
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights [Internet]. Lancet. 2021 ; 397( 10284): 1524-1527.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(21)00708-X
Vancouver
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights [Internet]. Lancet. 2021 ; 397( 10284): 1524-1527.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(21)00708-X
Artigo de periodico
Attention-deficit hyperactivity disorder (2020)
Posner, Jonathan; Polanczyk, Guilherme Vanoni ; Sonuga-barke, Edmund
Source: Lancet. Unidade: FM
Subjects: TRANSTORNO DO DEFICIT DE ATENÇÃO COM HIPERATIVIDADE, ESTIMULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POSNER, Jonathan e POLANCZYK, Guilherme Vanoni e SONUGA-BARKE, Edmund. Attention-deficit hyperactivity disorder. Lancet, v. 395, n. 10222, p. 450-462, 2020Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)33004-1. Acesso em: 06 out. 2024.
APA
Posner, J., Polanczyk, G. V., & Sonuga-barke, E. (2020). Attention-deficit hyperactivity disorder. Lancet, 395( 10222), 450-462. doi:10.1016/S0140-6736(19)33004-1
NLM
Posner J, Polanczyk GV, Sonuga-barke E. Attention-deficit hyperactivity disorder [Internet]. Lancet. 2020 ; 395( 10222): 450-462.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)33004-1
Vancouver
Posner J, Polanczyk GV, Sonuga-barke E. Attention-deficit hyperactivity disorder [Internet]. Lancet. 2020 ; 395( 10222): 450-462.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)33004-1
Artigo de periodico-carta/editorial
Tranexamic acid for traumatic brain injury [Carta] (2020)
Solla, Davi J. Fontoura; Rubiano, Andres Mariano; Teixeira, Manoel Jacobsen ; Andrade, Almir Ferreira de; Paiva, Wellingson Silva
Source: Lancet. Unidade: FM
Subjects: RISCO, COLETA DE DADOS, EFETIVIDADE, HEMATOMA, PESQUISA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOLLA, Davi J. Fontoura et al. Tranexamic acid for traumatic brain injury [Carta]. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://observatorio.fm.usp.br/handle/OPI/36906. Acesso em: 06 out. 2024. , 2020
APA
Solla, D. J. F., Rubiano, A. M., Teixeira, M. J., Andrade, A. F. de, & Paiva, W. S. (2020). Tranexamic acid for traumatic brain injury [Carta]. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de https://observatorio.fm.usp.br/handle/OPI/36906
NLM
Solla DJF, Rubiano AM, Teixeira MJ, Andrade AF de, Paiva WS. Tranexamic acid for traumatic brain injury [Carta] [Internet]. Lancet. 2020 ; 396( 10245): 162-163.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/36906
Vancouver
Solla DJF, Rubiano AM, Teixeira MJ, Andrade AF de, Paiva WS. Tranexamic acid for traumatic brain injury [Carta] [Internet]. Lancet. 2020 ; 396( 10245): 162-163.[citado 2024 out. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/36906
Artigo de periodico
Brazil’s unified health system: the first 30 years and prospects for the future (2019)
Castro, Marcia C; Massuda, Adriano; Almeida, Gisele; Menezes-Filho, Naércio Aquino ; Andrade, Mônica Viegas; Noronha, Kenya Valéria Micaela de Souza; Rocha, Rudi; Macinko, James; Hone, Thomas; Tasca, Renato; Giovanella, Lígia; Malik, Ana Maria; Werneck, Heitor; Fachini, Luiz Augusto; Atun, Rifat A
Source: Lancet. Unidade: FEA
Subjects: SAÚDE PÚBLICA, POLÍTICA DE SAÚDE, SISTEMA DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CASTRO, Marcia C et al. Brazil’s unified health system: the first 30 years and prospects for the future. Lancet, v. 394, n. 10195, p. 345-356, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)31243-7. Acesso em: 06 out. 2024.
APA
Castro, M. C., Massuda, A., Almeida, G., Menezes-Filho, N. A., Andrade, M. V., Noronha, K. V. M. de S., et al. (2019). Brazil’s unified health system: the first 30 years and prospects for the future. Lancet, 394( 10195), 345-356. doi:10.1016/S0140-6736(19)31243-7
NLM
Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, Noronha KVM de S, Rocha R, Macinko J, Hone T, Tasca R, Giovanella L, Malik AM, Werneck H, Fachini LA, Atun RA. Brazil’s unified health system: the first 30 years and prospects for the future [Internet]. Lancet. 2019 ; 394( 10195): 345-356.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)31243-7
Vancouver
Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, Noronha KVM de S, Rocha R, Macinko J, Hone T, Tasca R, Giovanella L, Malik AM, Werneck H, Fachini LA, Atun RA. Brazil’s unified health system: the first 30 years and prospects for the future [Internet]. Lancet. 2019 ; 394( 10195): 345-356.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)31243-7
Artigo de periodico-carta/editorial
Alcohol consumption and vascular disease: other points to consider (2019)
Chen, Che-Hong; Ferreira, Julio Cesar Batista ; Mochly-Rosen, Daria; Gross, Eric R
Source: Lancet. Unidade: ICB
Subjects: ANATOMIA, DOENÇAS VASCULARES, ACIDENTE VASCULAR CEREBRAL, ALCOOLISMO, TABAGISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHEN, Che-Hong et al. Alcohol consumption and vascular disease: other points to consider. Lancet. London: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S0140-6736(19)31880-X. Acesso em: 06 out. 2024. , 2019
APA
Chen, C. -H., Ferreira, J. C. B., Mochly-Rosen, D., & Gross, E. R. (2019). Alcohol consumption and vascular disease: other points to consider. Lancet. London: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/S0140-6736(19)31880-X
NLM
Chen C-H, Ferreira JCB, Mochly-Rosen D, Gross ER. Alcohol consumption and vascular disease: other points to consider [Internet]. Lancet. 2019 ; 394( 10209): 1617-1618.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)31880-X
Vancouver
Chen C-H, Ferreira JCB, Mochly-Rosen D, Gross ER. Alcohol consumption and vascular disease: other points to consider [Internet]. Lancet. 2019 ; 394( 10209): 1617-1618.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)31880-X
Artigo de periodico
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019)
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulieres, Denis; Tahara, Makoto; Castro Junior, Gilberto de Castro ; Psyrri, Amanda; Baste, Neus; Neupane, Prakash; Bratland, Ase
Source: Lancet. Unidade: FM
Subjects: CARCINOMA DE CÉLULAS ESCAMOSAS, NEOPLASIAS DE CABEÇA E PESCOÇO, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, v. 394, n. 10212, p. 1915-1928, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(19)32591-7. Acesso em: 06 out. 2024.
APA
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394( 10212), 1915-1928. doi:10.1016/S0140-6736(19)32591-7
NLM
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Vancouver
Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Baste N, Neupane P, Bratland A. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [Internet]. Lancet. 2019 ; 394( 10212): 1915-1928.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(19)32591-7
Artigo de periodico
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019)
Mok, Tony S. K; Wu, Yi-Long; Kudaba, Iveta; Kowalski, Dariusz M; Cho, Byoung Chul; Turna, Hande Z; Castro Junior, Gilberto de; Srimuninnimit, Vichien; Laktionov, Konstantin K; Bondarenko, Igor
Source: Lancet. Unidade: FM
Subjects: NEOPLASIAS PULMONARES, IMUNOHISTOQUÍMICA, QUIMIOTERAPIA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOK, Tony S. K et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, v. 393, n. 10183, p. 1819-1830, 2019Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32409-7. Acesso em: 06 out. 2024.
APA
Mok, T. S. K., Wu, Y. -L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393( 10183), 1819-1830. doi:10.1016/S0140-6736(18)32409-7
NLM
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Vancouver
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro Junior G de, Srimuninnimit V, Laktionov KK, Bondarenko I. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [Internet]. Lancet. 2019 ; 393( 10183): 1819-1830.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32409-7
Artigo de periodico
Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility (2018)
Ejzenberg, Dani; Andraus, Wellington; Mendes, Luana Regina Baratelli Carelli; Ducatti, Liliana; Song, Alice; Tanigawa, Ryan; Rocha-Santos, Vinicius; Arantes, Rubens Macedo; Soares Júnior, Jose Maria; Serafini, Paulo Cesar; Francisco, Rossana Pulcineli Vieira; Albuquerque, Luiz Augusto Carneiro D; Baracat, Edmund Chada
Source: Lancet. Unidade: FM
Subjects: ÚTERO, INFERTILIDADE FEMININA, GRAVIDEZ, PARTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EJZENBERG, Dani et al. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility. Lancet, v. 392, n. 10165, p. 2697-2704, 2018Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)31766-5. Acesso em: 06 out. 2024.
APA
Ejzenberg, D., Andraus, W., Mendes, L. R. B. C., Ducatti, L., Song, A., Tanigawa, R., et al. (2018). Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility. Lancet, 392( 10165), 2697-2704. doi:10.1016/S0140-6736(18)31766-5
NLM
Ejzenberg D, Andraus W, Mendes LRBC, Ducatti L, Song A, Tanigawa R, Rocha-Santos V, Arantes RM, Soares Júnior JM, Serafini PC, Francisco RPV, Albuquerque LACD, Baracat EC. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility [Internet]. Lancet. 2018 ; 392( 10165): 2697-2704.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)31766-5
Vancouver
Ejzenberg D, Andraus W, Mendes LRBC, Ducatti L, Song A, Tanigawa R, Rocha-Santos V, Arantes RM, Soares Júnior JM, Serafini PC, Francisco RPV, Albuquerque LACD, Baracat EC. Livebirth after uterus transplantation from a deceased donor in a recipient with uterine infertility [Internet]. Lancet. 2018 ; 392( 10165): 2697-2704.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)31766-5
Artigo de periodico
Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018)
Dicker, Daniel; Nguyen, Grant; Abate, Degu; Abate, Kalkidan Hassen; Abay, Solomon M; Abbafati, Cristiana; Abbasi, Nooshin; Abbastabar, Hedayat; Abd-Allah, Foad; Abdela, Jemal; Furtado, João Marcello Fortes
Source: Lancet. Unidade: FMRP
Subjects: MORTALIDADE, EPIDEMIOLOGIA ANALÍTICA, CONDIÇÕES DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DICKER, Daniel et al. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, v. 392, n. 10159, p. 1684-1735, 2018Tradução . . Disponível em: https://doi.org/10.1016/s0140-6736(18)31891-9. Acesso em: 06 out. 2024.
APA
Dicker, D., Nguyen, G., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., et al. (2018). Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392( 10159), 1684-1735. doi:10.1016/s0140-6736(18)31891-9
NLM
Dicker D, Nguyen G, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Furtado JMF. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2018 ; 392( 10159): 1684-1735.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/s0140-6736(18)31891-9
Vancouver
Dicker D, Nguyen G, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Furtado JMF. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 [Internet]. Lancet. 2018 ; 392( 10159): 1684-1735.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/s0140-6736(18)31891-9
Artigo de periodico
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 (2018)
Fullman, N; Abebe, Z; Santos, Itamar de Souza; Agarwal, G; Agius, D; Agrawal, A
Source: Lancet. Unidade: HU
Subjects: ASSISTÊNCIA À SAÚDE, ANÁLISE GLOBAL, EPIDEMIOLOGIA ANALÍTICA, ACESSO AOS SERVIÇOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FULLMAN, N et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, v. 391, n. ju 2018, p. 2236-2271, 2018Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)30994-2. Acesso em: 06 out. 2024.
APA
Fullman, N., Abebe, Z., Santos, I. de S., Agarwal, G., Agius, D., & Agrawal, A. (2018). Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, 391( ju 2018), 2236-2271. doi:10.1016/S0140-6736(18)30994-2
NLM
Fullman N, Abebe Z, Santos I de S, Agarwal G, Agius D, Agrawal A. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 [Internet]. Lancet. 2018 ; 391( ju 2018): 2236-2271.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30994-2
Vancouver
Fullman N, Abebe Z, Santos I de S, Agarwal G, Agius D, Agrawal A. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016 [Internet]. Lancet. 2018 ; 391( ju 2018): 2236-2271.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30994-2
Artigo de periodico-carta/editorial
Chagas disease cardiomyopathy treatment remains a challenge (2018)
Bocchi, Edimar
Source: Lancet. Unidade: FM
Subjects: DOENÇA DE CHAGAS, MIOCARDIOPATIA CHAGÁSICA, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar. Chagas disease cardiomyopathy treatment remains a challenge. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S0140-6736(18)30751-7. Acesso em: 06 out. 2024. , 2018
APA
Bocchi, E. (2018). Chagas disease cardiomyopathy treatment remains a challenge. Lancet. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/S0140-6736(18)30751-7
NLM
Bocchi E. Chagas disease cardiomyopathy treatment remains a challenge [Internet]. Lancet. 2018 ; 391( 10136): 2209-2209.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30751-7
Vancouver
Bocchi E. Chagas disease cardiomyopathy treatment remains a challenge [Internet]. Lancet. 2018 ; 391( 10136): 2209-2209.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30751-7
Artigo de periodico
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data (2018)
Head, Stuart J.; Hueb, Whady Armindo
Source: Lancet. Unidade: FM
Subjects: MORTALIDADE, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA, COMPLICAÇÕES PÓS-OPERATÓRIAS, METANÁLISE, SEGUIMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEAD, Stuart J. e HUEB, Whady Armindo. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, v. 391, n. 10124, p. 939-948, 2018Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)30423-9. Acesso em: 06 out. 2024.
APA
Head, S. J., & Hueb, W. A. (2018). Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet, 391( 10124), 939-948. doi:10.1016/S0140-6736(18)30423-9
NLM
Head SJ, Hueb WA. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data [Internet]. Lancet. 2018 ; 391( 10124): 939-948.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30423-9
Vancouver
Head SJ, Hueb WA. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data [Internet]. Lancet. 2018 ; 391( 10124): 939-948.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)30423-9
Artigo de periodico
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial (2018)
Bohula, Erin A.; Scirica, Benjamin M; Inzucchi, Silvio E; Mcguire, Darren K; Keech, Anthony C; Smith, Steven R; Kanevsky, Estella; Murphy, Sabina A; Leiter, Lawrence A; Nicolau, Jose Carlos
Source: Lancet. Unidade: FM
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, OBESIDADE, SOBREPESO, RECEPTORES DE SUBSTÂNCIAS ENDÓGENAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOHULA, Erin A. et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, v. 392, n. 10161, p. 2269-2279, 2018Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32328-6. Acesso em: 06 out. 2024.
APA
Bohula, E. A., Scirica, B. M., Inzucchi, S. E., Mcguire, D. K., Keech, A. C., Smith, S. R., et al. (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, 392( 10161), 2269-2279. doi:10.1016/S0140-6736(18)32328-6
NLM
Bohula EA, Scirica BM, Inzucchi SE, Mcguire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Nicolau JC. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial [Internet]. Lancet. 2018 ; 392( 10161): 2269-2279.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32328-6
Vancouver
Bohula EA, Scirica BM, Inzucchi SE, Mcguire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Nicolau JC. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial [Internet]. Lancet. 2018 ; 392( 10161): 2269-2279.[citado 2024 out. 06 ] Available from: https://doi.org/10.1016/S0140-6736(18)32328-6

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration